Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis

Drug Safety

Volumn 29, Issue 3, 2006, Pages 231-236

  Uzan, Laurent ^a   Guignat, Laurence ^a   Meune, Christophe ^a   Mouly, St́ephane ^b   Weber, Simon ^a   Bertagna, Xavier ^a   Bertherat, J́er̂ome ^a   Thomopoulos, Pierre ^a   Duboc, Denis ^a  

^a Rene Descartes University ^*  (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; CORTICOSTEROID DERIVATIVE; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DISEASE EXACERBATION; DRUG FATALITY; DRUG WITHDRAWAL; EUTHYROIDISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; PRIORITY JOURNAL; RECURRENCE RISK; THYROTOXICOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; TACHYCARDIA, SUPRAVENTRICULAR; THYROTOXICOSIS; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 33644840412     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629030-00006     Document Type: Article

References (24)

1. Dorian P, Mangat I. Role of amiodarone in the era of the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2003; 14: S78-81
2. Auer J, Berent R, Eber B. Amiodarone in the prevention and treatment of arrhythmia. Curr Opin Invest Drugs 2002; 3: 1037-44
3. Nichol G, McAlister F, Pham B, et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002; 87: 535-43
4. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001; 22: 1854-923
5. Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2001; 86: 3-8
6. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507-11
7. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9
8. Martino E, Bartalena L, Bogazzi F, et al. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-54
9. Savoie JC, Massin JP, Thomopoulos P, et al. Iodine-induced thyrotoxicosis in apparently normal thyroid glands. J Clin Endocrinol Metab 1975; 41: 685-91
10. Leger AF, Massin AP, Laurent MF, et al. Iodine-induced thyrotoxicosis: analysis of eighty-five consecutive cases. Eur J Clin Invest 1984; 14: 449-55
11. Bartalena L, Brogioni S, Grasso L, et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996; 81: 2930-3
12. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guidelines update for implantations of cardiac Pacemakers and antiarrhythmic devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2002; 40: 1703-19
13. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-40
14. Sakata K, Kurihara H, Iwamori K, et al. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. Am J Cardiol 1997; 80: 1522-7
15. Benza RL, Tallaj JA, Felker GM, et al. The impact of arrhythmia in acute heart failure. J Card Fail 2004; 10: 279-84
16. Nanthakumar K, Epstein AE, Kay GN, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2004; 44: 2166-72
17. Chalvidan T, Deharo JC, Dieuzaide P, et al. Near fatal electrical storm in a patient equipped with an implantable cardioverter defibrillator for Brugada syndrome. Pacing Clin Electrophysiol 2000; 23: 410-2
18. Credner SC, Klingenheben T, Mauss O, et al. Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 1998; 32: 1909-15
19. Manolis AG, Katsivas AG, Vassilopoulos C, et al. Electrical storm in an ICD-recipient with 429 delivered appropriate shocks: therapeutic management with antiarrhythmic drug combination. J Interv Card Electrophysiol 2002; 6: 91-4
20. Davies PH, Franklyn JA, Sheppard MC. Treatment of amiodarone induced thyrotoxicosis with carbimazole alone and continuation of amiodarone. BMJ 1992; 305: 224-5
21. Eaton SE, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol 2002; 56: 33-8
22. Osman F, Franklyn JA, Sheppard MC, et al. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 2002; 105: 1275-7
23. Bartalena L, Wiersinga WM, Tanda ML, et al. Diagnosis and management of amiodarone induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol 2004; 61: 494-502
24. Leenhardt A, Milliez P, Extramiana F, et al. Amiodarone is not definitively contraindicated in patients having experienced hyperthyroidism [abstract 3305]. Circulation 2001; 104 Suppl. II: II-701